ProQR Therapeutics NV
NASDAQ:PRQR
ProQR Therapeutics NV
NASDAQ:PRQR
Price:
2.01 USD
1.01%
Market Closed
Updated:
May 5, 2024
ProQR Therapeutics NV
Net Income (Common)
|
ProQR Therapeutics NV
Net Income (Common) Peer Comparison
Comparables:
PHARM
QURE
ARGX
MRUS
N
NAMS
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
ProQR Therapeutics NV
NASDAQ:PRQR
|
Net Income (Common)
-€28.1m
|
CAGR 3-Years
15%
|
CAGR 5-Years
5%
|
CAGR 10-Years
N/A
|
|
|
Pharming Group NV
AEX:PHARM
|
Net Income (Common)
-$10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Uniqure NV
NASDAQ:QURE
|
Net Income (Common)
-$308.5m
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-30%
|
CAGR 10-Years
-23%
|
|
|
argenx SE
XBRU:ARGX
|
Net Income (Common)
-$295.1m
|
CAGR 3-Years
21%
|
CAGR 5-Years
-32%
|
CAGR 10-Years
N/A
|
|
|
Merus NV
NASDAQ:MRUS
|
Net Income (Common)
-$154.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
N
|
NewAmsterdam Pharma Company NV
NASDAQ:NAMS
|
Net Income (Common)
-€78.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is ProQR Therapeutics NV's Net Income (Common)?
Net Income (Common)
-28.1m
EUR
-28.1m
EUR
Based on the financial report for Dec 31, 2023, ProQR Therapeutics NV's Net Income (Common) amounts to -28.1m EUR.
What is ProQR Therapeutics NV's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
5%
5%
Over the last year, the Net Income (Common) growth was 57%. The average annual Net Income (Common) growth rates for ProQR Therapeutics NV have been 15% over the past three years , 5% over the past five years .
You don't have any saved screeners yet
